Pinned
The FDA has accepted for review INOVIO’s BLA for lead candidate INO-3107 for the treatment of #RRP in adults, setting a PDUFA action date for October 30, 2026. Read more here: bit.ly/49wNNwA
INOVIO Pharmaceuticals
737 posts
INOVIO Pharmaceuticals
@InovioPharma
Trailblazers in the DNA medicine field, working to develop next-generation medicines to fight HPV-related disease, cancer and infectious disease.
- Today we initiated Phase 1 clinical testing of our #COVID19 DNA vaccine INO-4800. Up to 40 healthy volunteers will participate at two locations. Read more about this significant step forward in the global fight against COVID-19: bit.ly/2yyyc0x #DNAMedicines #DNAVaccines
- INOVIO announced we’ve been awarded $71 million from the U.S. @DeptofDefense to support large-scale manufacturing of INOVIO’s CELLECTRA® 3PSP device, which is used to deliver INOVIO’s COVID-19 DNA vaccine candidate. Details: bit.ly/2zX3zTN #DNAMedicines #DNAVaccines
- Today INOVIO announced interim Phase 1 data for INO-4800, our COVID-19 DNA vaccine candidate & its selection in Operation Warp Speed. Learn more about the safety and preliminary response results, along with animal challenge data: bit.ly/3eMpvQp #DNAMedicines #DNAVaccines
- We are honored to accept the "Best Therapeutic Vaccine Award" from the 13th Annual Vaccine Industry Excellence Awards for our HPV DNA medicine VGX-3100 targeting HPV-caused pre-cancers! #DNAMedicine #HPV #ViEAwards #WorldVaccineCongress
- We are excited to announce the initiation of the Phase 2 segment of our Phase 2/3 clinical trial for our #COVID19 DNA vaccine candidate, INO-4800. The Phase 2/3 trial will be funded by the U.S. Department of Defense. #DNAVaccines Read more: bit.ly/2UvLTFh
- Today we announced an INOVIO study published in peer-reviewed journal @NatureComms about the robust preclinical immune response, including both neutralizing antibodies and T cell responses, of INOVIO’s COVID-19 DNA vaccine: bit.ly/3bHGvFm #DNAMedicines #DNAVaccines
- INO-4800, INOVIO’s #COVID19 DNA vaccine candidate, showed positive results in protecting non-human primates from a live virus challenge 13 weeks after the last vaccination. See the full release here: bit.ly/2BInzdH #DNAMedicines #DNAVaccines
- Today we announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for our COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine. Link: sciencedirect.com/science/articl… Read more: bit.ly/3aA9gH8 #DNAMedicine #COVID19
- INOVIO is excited to have @thermofisher join our Manufacturing Consortium for our #COVID19 #DNAVaccine candidate, INO-4800. Read more here: bit.ly/2R5PisH
- We are proud to announce the publication in npj Vaccines of a pre-clinical ferret study that found no evidence the G-strain mutation of SARS-CoV-2 would adversely impact the efficacy of #COVID19 vaccine candidate INO-4800. #DNAMedicine #DNAVaccineMany COVID-19 vaccines in development were created with the original ‘D-strain’ of the SARS-CoV-2 virus. The dominant strain is now the ‘G-strain.’ But our newly published research found these vaccines should still work against it. #COVID19 #Coronavirus csiro.au/en/News/News-r…
- INOVIO and @IVIHeadquarters in partnership with Seoul National University Hospital dosed the first patient in a Phase 1/2 clinical trial of INOVIO's #COVID19 DNA vaccine candidate in South Korea. #DNAVaccines #DNAMedicines
- After meeting with President Trump, Vice President Pence, and the U.S. Coronavirus Task Force at the White House, we announced an accelerated timeline for developing DNA vaccine INO-4800 to address COVID-19. $INO #INOVIO #COVID19 Read more: ir.inovio.com/news-and-media…
